19 January 2016 - UCB today announced the European Commission has approved Briviact (brivaracetam) as an adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization (spreading to both sides of the brain after the initial seizure) in adult and adolescent patients from 16 years of age with epilepsy.

For more details, go to: http://www.ucb.com/presscenter/News/article/UCB-s-new-epilepsy-drug-BRIVIACT-receives-EU-approval-nbsp